Palvella Therapeutics, Inc. (PVLA) Stock Price & How to Invest
Last updated July 2026
Short answer
PVLA is Palvella Therapeutics, a clinical-stage rare-skin-disease biopharma whose value hinges almost entirely on QTORIN rapamycin, a topical gel that posted positive Phase 3 data in microcystic lymphatic malformations and is now in a rolling FDA new drug application. It trades like a binary, pre-revenue biotech story, so the picture is about pipeline execution and a well-funded balance sheet rather than current earnings.
PVLA stock price
As of 2026-07-17, Palvella Therapeutics, Inc. (PVLA) last closed at $157.24, up 432.8% over the past year. Over the past 52 weeks it has traded between $29.51 and $157.24.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Palvella Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Palvella Therapeutics, Inc. (PVLA) do?
Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company, founded in 2015 and based in Wayne, Pennsylvania, that develops therapies for serious, rare skin diseases with no FDA-approved treatments. Its platform is QTORIN, a proprietary topical (anhydrous gel) formulation of rapamycin. The lead program, QTORIN 3.9% rapamycin, targets microcystic lymphatic malformations (an estimated 30,000-plus U.S. patients) and carries FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations. In early 2026 the company reported positive topline Phase 3 SELVA results, began a rolling NDA submission mid-2026 with completion targeted for the second half of 2026, and pointed to potential U.S. approval in the first half of 2027. Additional programs include cutaneous venous malformations (TOIVA), angiokeratomas (LOTU), pachyonychia congenita, and QTORIN pitavastatin for DSAP.
The investment picture is a classic single-asset-led biotech: essentially no product revenue, ongoing net losses that widen as trials scale, and a valuation (a market cap around $1.7 billion in mid-2026) that reflects expectations for a first-in-disease franchise rather than current fundamentals. A February 2026 equity raise lifted cash and short-term investments to roughly $262 million, giving multi-year runway to reach approval and a potential launch. The outcome depends on FDA review, commercial uptake in small rare-disease markets, and the company's ability to expand QTORIN into multiple indications before cash is exhausted.
What's driving Palvella Therapeutics, Inc. (PVLA)?
1. QTORIN rapamycin approval path in microcystic LMs
The lead asset posted positive Phase 3 SELVA topline data, with the company citing significant improvement on the mLM-IGA scale. Palvella began a rolling NDA in mid-2026 and targets completion in the second half of 2026, with potential approval in the first half of 2027. Approval would make it the first FDA-cleared therapy for microcystic lymphatic malformations.
2. Pipeline expansion across rare dermatology
Beyond the lead indication, Palvella is advancing QTORIN rapamycin into cutaneous venous malformations (TOIVA/Phase 3 planned), angiokeratomas (LOTU Phase 2), and pachyonychia congenita, plus a separate QTORIN pitavastatin program for DSAP. A single topical platform addressing several rare conditions is the multi-indication thesis behind the valuation.
3. Regulatory designations and orphan positioning
QTORIN rapamycin holds Breakthrough Therapy, Orphan Drug, and Fast Track designations for microcystic LMs, plus Fast Track for venous malformations. These can support faster review and market exclusivity in indications with no approved competitors, which is central to the rare-disease pricing and moat argument.
4. Balance-sheet runway
A February 2026 offering raised roughly $230 million gross, lifting cash and short-term investments to about $262 million as of March 31, 2026. Management has said existing resources fund operations for well over a year, giving Palvella room to reach an approval decision and begin building commercial infrastructure without an immediate need to raise.
What are the risks to Palvella Therapeutics, Inc. (PVLA)?
As a pre-revenue clinical-stage biotech, Palvella has no product sales and reports growing net losses (about $15.8 million in Q1 2026), so results depend on future regulatory and commercial outcomes. FDA review of the rolling NDA could bring delays, a complete response letter, or a narrower label than hoped. Rare-disease markets are small, so even an approval may translate into modest revenue and slow uptake. Heavy concentration in one platform (QTORIN rapamycin) means a setback in the lead indication would weigh on the whole story. Ongoing R&D spending will likely require additional capital over time, which can dilute existing shareholders, and the stock is volatile around clinical and regulatory catalysts.
How is Palvella Therapeutics, Inc. (PVLA) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Palvella Therapeutics, Inc.'s investor relations page or your broker.
- Product revenue (TTM): ~$0 (pre-commercial)
- Net loss (Q1 2026): ~$15.8M
- R&D expense (Q1 2026): ~$9.3M
- Cash + short-term investments: ~$262M
- Market cap: ~$1.7B
- Analyst avg. price target: ~$230
Palvella generates essentially no product revenue and is valued on the expected commercial potential of QTORIN rapamycin, not current earnings. With roughly $262 million in cash against a market cap near $1.7 billion, the stock reflects optimism about a first-in-disease franchise. Standard earnings multiples do not apply to a pre-revenue biotech, so the balance sheet, trial data, and regulatory timeline matter more than valuation ratios.
Who competes with Palvella Therapeutics, Inc. (PVLA)?
Standard-of-care procedures (indirect)
In microcystic lymphatic malformations and related vascular anomalies there are no FDA-approved drugs, so current options are surgery, sclerotherapy, and laser therapy. These carry high recurrence and morbidity, which is the unmet need Palvella is targeting, but they represent the incumbent treatment approach a topical therapy must displace.
Rare-dermatology and orphan biotechs
Palvella competes for investor attention and clinical talent with other small and mid-cap rare-skin-disease developers pursuing orphan indications (for example companies working on genetic and inflammatory dermatoses). Off-label systemic or compounded rapamycin used by some specialists is also a reference point for its topical approach.
Larger dermatology and rare-disease pharma
Established dermatology and rare-disease players (large specialty pharma and biotech) could enter these indications, acquire competing assets, or serve as potential partners or acquirers. Their scale in commercialization is both a competitive risk and a possible source of strategic interest for a single-platform company.
How to invest in Palvella Therapeutics, Inc. (PVLA)
There are three common ways to get PVLA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so PVLA sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where PVLA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Palvella Therapeutics, Inc. (PVLA)
Palvella is a pre-revenue, pipeline-driven biotech whose case rests on getting QTORIN rapamycin approved and commercialized in rare dermatology, backed by a large cash cushion but no product sales yet.
More on Palvella Therapeutics, Inc. (PVLA)
Whether PVLA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PVLA a buy?, and where the stock could go from here in the PVLA stock forecast.
For income investors, whether PVLA pays a dividend and how the payout looks is covered in does PVLA pay a dividend?
Build a basket around PVLA with Walnut
Use Palvella Therapeutics, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Palvella Therapeutics do?
+
Palvella is a clinical-stage biopharmaceutical company developing therapies for serious, rare skin diseases that have no FDA-approved treatments. Its core technology is QTORIN, a proprietary topical anhydrous-gel formulation of rapamycin, led by a program for microcystic lymphatic malformations.
Is PVLA profitable or does it have revenue?
+
No. Palvella is a pre-revenue, clinical-stage company with no approved products, and it reports ongoing net losses (about $15.8 million in the first quarter of 2026) as it funds trials. Its value depends on future regulatory approval and commercialization rather than current earnings.
What is QTORIN rapamycin?
+
QTORIN rapamycin is Palvella's lead investigational therapy, a 3.9% topical rapamycin anhydrous gel. It is being developed first for microcystic lymphatic malformations and holds FDA Breakthrough Therapy, Orphan Drug, and Fast Track designations for that indication.
Where is QTORIN rapamycin in the approval process?
+
Palvella reported positive topline Phase 3 SELVA results in early 2026 and began a rolling FDA new drug application mid-year, with completion targeted for the second half of 2026 and potential U.S. approval in the first half of 2027, subject to FDA review.
How much cash does Palvella have?
+
As of March 31, 2026, Palvella reported about $262 million in cash, cash equivalents, and short-term investments, boosted by a February 2026 equity offering. Management has indicated this funds operations for well beyond a year while advancing its programs.
What other programs are in Palvella's pipeline?
+
Beyond microcystic lymphatic malformations, QTORIN rapamycin is being studied for cutaneous venous malformations, angiokeratomas, and pachyonychia congenita, and Palvella is developing QTORIN pitavastatin for DSAP (a genetic skin condition), with several trials planned to start in the second half of 2026.
What are the main risks with PVLA?
+
Key risks include FDA review outcomes for its lead asset, heavy reliance on one platform, small rare-disease market sizes that can limit revenue, ongoing losses, potential need for future capital raises that dilute shareholders, and high stock volatility around clinical and regulatory news.
Why is Palvella's market cap so large relative to its revenue?
+
As a pre-revenue biotech, PVLA is valued on the expected commercial potential of QTORIN across several rare indications rather than current sales. A market cap near $1.7 billion reflects investor optimism about a first-in-disease franchise, which also means the stock is sensitive to any pipeline setbacks.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Palvella Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.